Lakefront Biotherapeutics NV
LKFTDrugs in Pipeline
6
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Filgotinib
Rheumatoid Arthritis
GLPG3667
Systemic Lupus Erythematosus
GLPG3970
Ulcerative Colitis
GLPG0634
Rheumatoid Arthritis
GLPG1205
Ulcerative Colitis
Lanraplenib
Sjogren's Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Filgotinib | Phase 3 | Rheumatoid Arthritis | - | - |
GLPG3667 | Phase 2 | Systemic Lupus Erythematosus | - | - |
GLPG3970 | Phase 2 | Ulcerative Colitis | - | - |
GLPG0634 | Phase 2 | Rheumatoid Arthritis | - | - |
GLPG1205 | Phase 2 | Ulcerative Colitis | - | - |
Lanraplenib | Phase 2 | Sjogren's Syndrome | - | - |
Frequently asked questions
What is in Lakefront Biotherapeutics NV's drug pipeline?→
CatalystAlert tracks 6 drug candidates in Lakefront Biotherapeutics NV's (LKFT) pipeline across Phase 3, Phase 2. Its lead program is Filgotinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Lakefront Biotherapeutics NV's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Lakefront Biotherapeutics NV (LKFT) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track LKFT biotech catalysts?→
Add LKFT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Lakefront Biotherapeutics NV's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.